Ethiodized Oil

Adjuvant Therapy

Zhejiang UniversityPhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 81/ 100

Competitive context

27 Active assets in the Adjuvant Therapy cohort.

Asset / Sponsor	Phase	Rating
TAMOXIFEN Fujian Cancer Hospital	Phase 3	B
Letrozole Fujian Cancer Hospital	Phase 3	B
Arimidex Fujian Cancer Hospital	Phase 3	B
EXEMESTANE Fujian Cancer Hospital	Phase 3	B
TRASTUZUMAB Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 2/3	B

View all 30 →

Same molecule, other indications

Ethiodized Oil is also rated in:

hepatocellular carcinomaDormant

BB

Indicative ·

70 / 100

Colon Cancer Liver MetastasisDormant

BB

Indicative ·

66 / 100

Neoplastic Cells, CirculatingDormant

BB

Indicative ·

65 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.